CARLSBAD, Calif., May 25, 2023
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a
clinical-stage biotechnology company focused on developing
next-generation precision medicines that target large opportunities
in Fibroblast Growth Factor Receptor (FGFR) biology, today
announced that management will participate in the following
investor conferences:
- TD Cowen's 4th Annual Oncology Innovation Summit:
Todd Harris, CEO of TYRA, will
participate in a virtual fireside chat on Tuesday, May
30th, 11:00 am –
11:25 am ET.
- Jefferies Global Healthcare Conference, June 7-9, 2023: TYRA management will
participate in one-on-one meetings with investors during the
conference.
A live and archived webcast of the TD Cowen fireside chat will
be available via the For Investors page on the Investor
section of the TYRA website.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage
biotechnology company focused on developing next-generation
precision medicines that target large opportunities in FGFR
biology. The Company's in-house precision medicine platform, SNÅP,
enables rapid and precise drug design through iterative molecular
SNÅPshots that help predict genetic alterations most likely to
cause acquired resistance to existing therapies. TYRA's initial
focus is on applying its accelerated small molecule drug discovery
engine to develop therapies in targeted oncology and genetically
defined conditions. TYRA is based in Carlsbad, CA. For
more information about our science, pipeline and people, please
visit www.tyra.bio and engage with us
on LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-participate-in-upcoming-investor-conferences-301834600.html
SOURCE Tyra Biosciences